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Library screening by fragment-based docking
Abstract
We review our computational tools for high-throughput screening by fragment-based docking of large
collections of small molecules. Applications to six different enzymes, four proteases, and two protein
kinases, are presented. Remarkably, several low-micromolar inhibitors were discovered in each of the
high-throughput docking campaigns. Probable reasons for the lack of submicromolar inhibitors are the
tiny fraction of chemical space covered by the libraries of available compounds, as well as the
approximations in the methods employed for scoring, and the use of a rigid conformation of the target
protein. 
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Abstract
We review our computational tools for high-throughput screening by fragment-based
docking of large collections of small molecules. Applications to six different enzymes, four
proteases and two protein kinases, are presented. Remarkably, several low-micromolar
inhibitors were discovered in each of the high-throughput docking campaigns. Probable
reasons for the lack of submicromolar inhibitors are the tiny fraction of chemical space
covered by the libraries of available compounds, as well as the approximations in the
methods employed for efficient scoring, and the use of a rigid conformation of the target
protein.
Abbreviations: DAIM, decomposition and identification of molecules; FFLD, fast flex-
ible ligand docking; SEED, solvation energy for exhaustive docking; EphB4, ertythro-
poietin producing human hepatocellular carcinoma receptor tyrosine kinase B4; CDK2,
cyclin-dependent kinase 2.
1 Introduction
Among the many significant contributions to computational chemistry and physical chem-
istry, Martin Karplus has also pioneered the use of molecular fragments to map protein
binding sites. His paper with Andrew Miranker on the simultaneous minimization of mul-
tiple copies of small and mainly rigid functional groups in the protein force field (MCSS)
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can be considered as the first fragment-based procedure for drug discovery [1]. Ex-
perimental techniques for fragment-based lead identification, such as structure-activity
relationship by nuclear magnetic resonance spectroscopy [2], share the same essential
idea as the MCSS approach. Thus the importance of molecular fragments has been
recognized and exploited first by computational approaches [1, 3, 4]. More recently,
fragment-based drug discovery strategies have been developed using X-ray crystallogra-
phy [5], nuclear magnetic resonance spectroscopy [6], surface plasmon resonance [7], mass
spectrometry [8, 9], substrate activity screening (where the fragments are substrates later
converted into inhibitors [10, 11, 12]), and tethering [13, 14]. Experimental techniques
for fragment-based drug discovery have been discussed in previous reviews which con-
tain a large number of applications [15, 16, 17, 18, 19, 20]. Successful in vitro screening
campaigns have been reported for several targets, and a non-exhaustive list includes β-
secretase [7, 15, 21, 22], several protein kinases [23, 24, 25, 26, 27], DNA gyrase [28],
caspase [29, 30], anthrax lethal factor [31], and phosphodiesterase [32].
In this review, we focus on the computational methods for fragment-based docking
developed in our research group. We do not discuss in silico approaches developed by
others (reviewed in [33, 34, 35, 36]), but rather describe briefly our computational tools (in
section 2), and present applications (in section 3) to six different enzymes, four proteases
and two protein kinases. Notably, it has been possible to identify single-digit micromolar
inhibitors for all of the six enzymes by fragment-based docking of large libraries of small
molecules. In the Conclusions (section 4) we give possible reasons for the difficulties
encountered in discovering submicromolar inhibitors by in silico screening of collections
of available compounds.
2 High-throughput fragment-based docking
Two essential elements of our in silico screening approach are the fragment-based docking
procedure and the scoring based on force field energy [37] with continuum electrostatics
solvation [38, 39, 40, 41, 42]. The pipeline for high-throughput docking consists of four
consecutive steps (Figure 1): (1) Automatic decomposition of each molecule of the library
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into fragments [43], (2) fragment docking and ranking of poses [40, 41], (3) flexible docking
of each molecule of the library using the best poses of its fragments as anchors [44], (4)
evaluation of the binding free energy of multiple poses of each compound by the LIECE
method (linear interaction energy with continuum electrostatics [45]). The first three
steps are performed by computer programs developed in our research group. In the
fourth step, CHARMM [46, 47] is used for the energy minimization and finite-difference
Poisson calculations.
2.1 Decomposition of compounds into fragments
The automatic fragmentation of a molecule into substructures and the selection of the
three anchor fragments for docking (see below) are performed by the program DAIM (De-
composition And Identification of Molecules [43]). The decomposition generates mainly
rigid fragments which can be docked very efficiently (as explained in the next subsection).
The decomposition of a molecule consists of four steps: Ring identification, fragment def-
inition, functional group merging, and completion of the valences. (i) Rings are identified
by successively enumerating all neighbors (i.e., directly covalently bound atoms) of ev-
ery atom, similar to a breadth-first search. (ii) A fragment is defined as a set of atoms
connected by unbreakable bonds. The basic definition of unbreakable bonds includes ter-
minal, double, triple, aromatic bonds and bonds in rings. Non-rotatable and unbreakable
bonds are distinguished in DAIM; a non-rotatable bond is always unbreakable, whereas
the reverse is not true (e.g., a double bond is non-rotatable and unbreakable whereas
an amide bond is unbreakable, but can assume more than one conformation). (iii) To
form chemically relevant fragments and avoid the generation of many small groups, small
functional groups (e.g., -OH, -CH3, -CX3 [where X can be any halogen], -SO3, -CHO,
-NO2, -NH2 and -SH) are merged with the fragment they are connected to. Unbreakable
bonds and functional groups (points ii and iii, respectively) can be defined by the user.
(iv) In the final step, missing atom neighbors are added. An atom will lack a neighbor
atom whenever the bond connecting them has been cut. These missing neighbors are
replaced by hydrogen atoms to reconstitute the correct valence for every atom. A methyl
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group is used to fill valences where a hydrogen atom would result in an unwanted addi-
tional hydrogen bond direction (e.g., a hydrogen replacing a carbon atom bound to an
sp3 nitrogen).
2.2 Docking of anchor fragments
The docking approach implemented in the program SEED determines optimal positions
and orientations of small to medium-size molecular fragments in the binding site of a
protein [40, 41]. Apolar fragments are docked into hydrophobic regions of the receptor
while polar fragments are positioned such that at least one intermolecular hydrogen bond
is formed. Each fragment is placed at several thousand different positions with multiple
orientations (for a total of in the order of 106 poses) and the binding energy is estimated
whenever severe clashes are not present (usually about 105 poses). The binding energy is
the sum of the van der Waals interaction and the electrostatic energy. The latter consists
of screened receptor-fragment interaction, as well as receptor and fragment desolvations
calculated by an efficient numerical implementation of the generalized Born approach [39].
2.3 Flexible docking of library compounds
The flexible-ligand docking approach FFLD uses a genetic algorithm and a very efficient
scoring function [44, 48]. The random perturbations (i.e., sampling) in the genetic al-
gorithm affect only the conformation of the ligand; its placement in the binding site is
determined by the SEED anchors and a least square fitting method [49]. In this way
the position and orientation of the ligand in the binding site are determined by the best
binding modes of its fragments previously docked by SEED. On the other hand, the
scoring function used in FFLD is based on van der Waals and hydrogen bond terms and
does not explicitly include solvation for efficiency reasons. Solvation effects are implicitly
accounted for because the poses of the fragments are previously sorted according to force
field energy with electrostatic solvation in SEED. FFLD requires three not-necessarily
different fragments to place a flexible ligand unambiguously in the binding site, e.g., the
fluorobenzene, morpholine, and benzoic acid of compound 2 (Table 1). The automatic
definition of the three anchor fragments for each molecule of the library is performed by
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DAIM using the chemical richness, i.e., the sum of all entries in the DAIM fingerprint [43].
2.4 LIECE binding energy evaluation
The essential idea of linear interaction energy (LIE) models is that the free energy of
complex formation can be calculated by considering only the end points of the thermo-
dynamic cycle of ligand binding, i.e., bound and free states. For this purpose, one usually
calculates average values of interaction energies from molecular dynamics simulations of
the isolated ligand and the ligand/protein complex [50, 51]. The free energy of binding
is approximated by
∆G = α
(
〈EvdW 〉bound − 〈E
vdW 〉free
)
+ β
(
〈Eelec〉bound − 〈E
elec〉free
)
(1)
where EvdW and Eelec are the van der Waals and electrostatic interaction energies between
the ligand and its environment. The environment is either the solvent (free) or both
the protein and solvent (bound). The 〈〉 denotes an ensemble average sampled over a
molecular dynamics [50] or Monte Carlo [52] trajectory. The coefficient α is determined
empirically [50]. Originally, β was fixed to a value of 1/2, as predicted by the linear
response approximation [50]. Later studies have shown, however, that improved models
for a large variety of systems could be obtained by considering β as a free parameter [53].
Consequently, both coefficients are obtained by a fit of experimentally determined values
of ∆G to the calculated values of Eelec and EvdW for a training set of known ligands.
The original LIE method and modifications thereof have been applied to a large
number of existing inhibitor/protein datasets [50, 54, 55, 56, 57, 58, 59]. Moreover,
LIE-based scorings of ligands were shown to perform better than established scoring
functions [60]. Interestingly, recent applications to pharmaceutically relevant enzyme
targets have documented the predictive ability and usefulness in lead-discovery projects.
As an example, the LIE method with explicit water molecular dynamics sampling was
successfully used in the design of a series of inhibitors of the malarial aspartic proteases
plasmepsin I and II [61]. Unfortunately, LIE cannot be used for high-throughput docking
because of its computational requirements (the currently fastest implementation needs
about six hours for each compound [60]). Therefore, we have replaced the explicit water
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molecular dynamics (or Monte Carlo) simulations with a simple energy minimization and
combined the LIE method with a rigorous treatment of solvation within the continuum
electrostatics approximation [45], i.e., the numerical solution of the Poisson equation by
the finite-difference technique [62]. The LIECE approach, where the last two letters stand
for continuum electrostatics, is about two orders of magnitude faster than previous LIE
methods and shows a similar precision on the targets tested. In fact, we have observed
an error of about 1 kcal/mol for 13 and 29 peptidic inhibitors of β-secretase and HIV-1
protease, respectively [45]. Similar accuracy has been reported for other proteases [63, 64]
and five kinases [65].
2.5 Consensus scoring
It has been reported that consensus scoring is generally preferable to the use of a single
scoring function [66]. Furthermore, the median rank is more suitable than the average
rank in consensus-scoring because the former is less sensitive to outliers [67]. Rank by
median consensus scoring was used in the in silico screening against plasmepsin and
cathepsin B (Table 1). For plasmepsin, consensus scoring was preferred to ranking by
LIECE because visual inspection of the best LIECE poses revealed several unlikely bind-
ing modes. In the case of cathepsin B, the lack of experimental data on inhibitors binding
outside the catalytic center was the reason for not using LIECE which requires at least
10-15 binding affinity data points for fitting the 2-3 parameters of the linear model.
3 In silico screening campaigns
During 2004-2008, our suite of programs for fragment-based docking [43, 40, 44] has been
employed in eight in silico screening campaigns on six different enzymes which play a
key role in a variety of diseases (Table 1). Four of these enzymes are proteases of three
different classes (aspartic, serine, and cysteine proteases), while the remaining two are a
tyrosine kinase and a Ser/Thr kinase. The 2D structures of the most potent inhibitors
discovered in the eight high-throughput docking campaigns are shown in Figure 2.
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3.1 β-Secretase (Alzheimer’s disease)
Alzheimer’s disease is the most common neurodegenerative disease and it accounts for
the majority of the cases of dementia diagnosed after the age of 60 [68]. Amyloid plaques,
which are found in the post-mortem brain of Alzheimer’s disease patients [69, 70], consist
mainly of fibrillar aggregates of the Aβ peptide, a proteolytic cleavage product of the β-
amyloid precursor protein (APP). Two enzymes, γ- and β-secretase (β-site APP cleaving
enzyme) are responsible for the sequential processing of APP [71]. Although it is not
clear whether the plaques or oligomeric prefibrillar species are responsible for neuronal
loss and dementia [72], the pepsin-like aspartic protease β-secretase has become one of
the major Alzheimer’s disease targets [68, 73, 74, 75, 76, 77]. β-Secretase inhibitors have
been shown to lower brain Aβ after direct intracranial administration [76, 78] or via
peripheral administration at relatively high doses in murine models [75, 76]. Moreover, a
novel potent tertiary carbinamine inhibitor of β-secretase effectively lowers Aβ levels in
a nonhuman primate model [77].
β-Secretase is not an easy target to block [68, 73, 79, 80, 81]. For instance, only
a single molecule (1,3,5-trisubstituted benzene) emerged as β-secretase inhibitor from a
multimillion compound library submitted to a high-throughput screening campaign [82].
As a proof-of-principle of our in silico screening approach, high-throughput fragment-
based docking into the β-secretase active site and LIECE binding free energy evaluation
has led to the discovery of three novel series of inhibitors: phenylurea derivatives (e.g.,
compound 1) [83], triazine derivatives (e.g., compound 2) [84], and a set of five cell-
permeable, nonpeptide, low-micromolar inhibitors with a different scaffold (D. Huang
and A. Caflisch, unpublished results). Among them, the phenylurea derivatives were
identified from an initial set of about half a million molecules [83] (Table 1). Twelve of
the 72 tested compounds inhibit β-secretase in at least one of two different mammalian
cell-based assays (EC50 < 10 µM). It is important to note that for almost all of the
12 compounds, for which an EC50 value could be measured, the discrepancies between
LIECE-predicted affinity and the experimental value is within the LIECE accuracy of
about 1 kcal/mol [45]. The triazine derivatives were selected from an initial set of about
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300000 [84]. Ten of the 88 tested compounds inhibit β-secretase activity in an enzymatic
assay (IC50 < 100 µM), and four of them are active in a mammalian cell-based assay
(EC50 < 20 µM).
3.2 P. falciparum plasmepsin II (malaria)
An estimated 40% of the world’s population is a potential victim of malaria, which is
responsible for 300-660 million infections annually [85]. Furthermore, there is an urgent
need to develop new antimalarial medicines because of the emerging drug resistance [86].
Plasmepsins are pepstatin-like aspartic proteases unique to the malaria parasites (which
belong to the genus Plasmodium). They are involved in metabolism and host cell in-
vasion [87]. Ten plasmepsins have been identified in the genome of P. falciparum, the
plasmodium species that causes the most fatal form of malaria in human, and four of these
10 are located in the food vacuole, an acidic lysosome-like organelle in which haemoglobin
degradation takes place. It has been shown that inhibitors of plasmepsins are fatal to
the parasites [88], which suggests that plasmepsins are pharmaceutically relevant targets.
Furthermore, several small-molecule inhibitors of retroviral and human aspartic proteases,
namely HIV-protease [89] and renin [90], are effective and safe medicines, which provides
additional support to the relevance of plasmepsins as drug targets.
We used our fragment-based docking procedure to search for inhibitors of plasmepsin II
[63]. A total of 4.6 million compounds were first clustered according to 2D structural
similarity resulting in about 40000 molecules which were then used for fragment-based
docking. Docking into the plasmepsin II active site was followed by consensus scoring
using four force field-based energy functions. A total of 19 compounds were tested in
an enzymatic assay, and three of them showed single-digit micromolar inhibitory activity
(Table 1) [63]. One of these three inhibitors is halofantrine (compound 3), an antimalar-
ial drug discovered more than 40 years ago whose mechanism of action is still unknown.
To better investigate the binding mode of halofantrine, four 50-ns molecular dynamics
simulations with explicit solvent were performed starting from two different poses, one
generated by automatic docking and the other by manual fitting with the help of a com-
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puter graphics program. The molecular dynamics simulations indicate that the binding
mode generated by fragment-based docking is more stable than the one obtained by
manual docking although it is not possible to definitively discard either [63].
3.3 West Nile virus NS3 protease (flaviviral infections)
The pathogenic members of the flavivirus family, e.g., West Nile virus and the closely
related Dengue virus, are transmitted by mosquito bites. Although an estimated 2.5
billion people are potential victims of encephalitis and other fatal maladies caused by
flaviviruses [91], these diseases have received much less attention than other tropical
diseases like avian influenza. Their status as ”neglected” diseases is in part due to the
fact that flaviviruses are widespread mainly in poor countries, and mosquitos can fly only
much shorter distances than migratory birds so that they do not represent a threat in
developed countries. Recently, the non-structural 3 (NS3) protease has been shown to be
responsible for cleavage of the viral polyprotein precursor and to play a pivotal role in
the replication of flaviviruses [92, 93]. In fact, site directed mutagenesis focused on the
NS3 protease cleavage sites in the polyprotein precursor abolishes viral infectivity [93].
Therefore, the NS3 protease is one of the most promising targets for drug development
against flaviviridae infections. In this context it is important to note that two inhibitors
of the closely related hepatitis C virus protease are under late-stage clinical development
[94, 95, 96, 97].
We have run two in silico screening campaigns to identify inhibitors of the West Nile
virus NS3 protease. The first high-throughput docking campaign (Figure 3, left) was
performed on the X-ray structure of the protease [64] while the second campaign (Figure 3,
right) made use of a snapshot selected along a 1-ns explicit solvent molecular dynamics
simulation started from the crystal structure [98]. This snapshot was chosen from a set
of 100 as it optimally accommodates three representative molecular fragments: benzene
and two functional groups with a positive charge. The former is the most common ring
in the known drugs, while the latters were employed because the active site of the NS3
protease has a large amount of hydrogen bond acceptors. Interestingly, the hit rate was
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high in both campaigns (5% and 40%, Table 1). Most importantly, inhibitors 4 and 5
are candidate lead compounds. They occupy only the S1 and S2 pockets of the substrate
binding site (Figure 4), so that additional substituents are expected to improve their
affinity and, at the same time, retain good druglike properties as they both have very
favorable ligand efficiency (which is defined as the experimentally measured free energy
of binding divided by the number of non-hydrogen atoms [99]). The in silico discovery
of compounds 4 and 5 is remarkable because the West Nile virus NS3 protease is a very
difficult target. Very few nonpeptidic inhibitors have been reported. Moreover, less than
10 molecules emerged as inhibitors (in the micromolar range) from a library of more than
one million compounds submitted to a high-throughput in vitro screening campaign [100].
It is interesting to note that compound 5, as well as another inhibitor of the West
Nile virus NS3 protease discovered by docking into the molecular dynamics snapshot
(the diphenylesther 2 in [98]), would not have been identified by docking into the X-ray
structure, as the S1 pocket in the latter does not accommodate the benzene ring in an
energetically favorable way [98].
3.4 Cathepsin B (cancer and rheumatic disorders)
Cathepsin B is capable of endopeptidase [101], peptidyl-dipeptidase [102, 103], and car-
boxypeptidase activities [104, 105]. Among the cysteine peptidases cathepsin B is unique
for the presence of a flexible segment, known as the occluding loop, that can block the
primed subsites of the substrate binding cleft. With the occluding loop in the open con-
formation cathepsin B acts as an endopeptidase, while it acts as an exopeptidase when
the loop is closed. Cathepsin B is involved in a number of human disorders. It activates
trypsinogen in hereditary pancreatitis [106], participates in apoptosis [107], tumor pro-
gression and malignancy [108, 109], and plays an important role in rheumatic diseases
[110, 111, 112].
We have targeted the occluding loop of human cathepsin B outside the catalytic
center, using high-throughput fragment-based docking [113]. The aim was to identify in-
hibitors that would interact with the occluding loop thereby modulating enzyme activity
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without the help of chemical warheads (i.e., without reactive functional groups that form
a covalent bond with residues in the catalytic site but usually also bind unspecifically
to other proteins). From a library of about 48000 compounds, the in silico approach
identified compound 6 which fulfills the working hypothesis (Table 1). This molecule
possesses two distinct binding moieties and behaves as a reversible, double-headed com-
petitive inhibitor of cathepsin B by excluding synthetic and protein substrates from the
active center. The kinetic mechanism of inhibition suggests that the occluding loop is
stabilized in its closed conformation, mainly by hydrogen bonds with the inhibitor, thus
decreasing endoproteolytic activity of the enzyme. Furthermore, the dioxothiazolidine
head of compound 6 sterically hinders binding of the C-terminal residue of substrates re-
sulting in inhibition of the exopeptidase activity of cathepsin B in a physiopathologically
relevant pH range [113].
3.5 EphB4 tyrosine kinase (cancer)
The protein kinase EphB4 (ertythropoietin producing human hepatocellular carcinoma
receptor tyrosine kinase B4) is a highly attractive angiogenic target involved in many
types of cancer [114]. It seems to be rather recalcitrant to inhibition because, despite its
potential therapeutic importance, very few inhibitors have been reported in the literature
up to date.
We have developed and applied the ALTA (anchor-based library tailoring) approach
to identify ATP-competitive inhibitors of EphB4 [115] (Figure 5). ALTA is an auto-
matic fragment-based procedure for focusing libraries of compounds. First, molecular
fragments are docked and prioritized (i.e., anchors are selected based on a ranking) ac-
cording to force field energy which includes continuum electrostatics solvation [40, 39].
Large collections of molecules can then be effectively reduced in size by selecting only
the compounds that have one (or more) fragment among the top ranking anchors. In
principle, ALTA does not require any information about known inhibitors but in the ap-
plication to the EphB4 kinase pharmacophore knowledge (hydrogen bonds to the hinge
region) was additionally used to efficiently reduce the size of the original library from
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about 728000 to 21418 molecules. Two series of novel EphB4 inhibitors have been iden-
tified by ALTA. Compound 7 is a potential candidate for further development because
of its low-micromolar affinity and molecular weight of only 337 DA which result in a very
favorable ligand efficiency (Table 1). Moreover, the kinetic characterization of a very sim-
ilar compound (2 in Table I of [115]) indicates that this series of molecules bind to the
ATP-binding site, as predicted by the docking calculations [115]. Recently, single-digit
nanomolar affinities have been reached by chemical synthesis of derivatives of compound
7 that were designed on the basis of the binding mode obtained by docking [116].
3.6 CDK2 Ser/Thr kinase (cancer)
The human cyclin-dependent kinase 2 (CDK2) is a Ser/Thr kinase that controls cell
cycle progression in proliferating eukaryotic cell [117, 118, 119]. The activity of CDK2 is
tightly controlled, and fully activated CDK2 is essential for proper S phase progression.
Studies have shown that inhibition of CDK2/cyclin A during S phase leads to S phase
arrest and apoptosis, which has suggested a pharmacological role for CDK2 inhibitors in
the treatment of cancer [120].
A diversity set of 40375 compounds was used for fragment-based docking into the
X-ray structure of CDK2 (PDB code 1KE5). A threshold in the ratio between van der
Waals energy and molecular weight, and the presence of at least one key hydrogen bond
were used as filters to discard unfavorable poses. The remaining poses were scored by the
two-parameter LIECE model fitted on 73 known CDK2 inhibitors. Thirty compounds
were tested in an enzymatic assay, and compound 8 emerged with a single-digit micro-
molar IC50 value and a favorable ligand efficiency (0.32 kcal/mol per non-hydrogen atom,
Table 1) [65].
4 Conclusions
Low micromolar inhibitors of four proteases and two protein kinases have been identified
by high-throughput screening using fragment-based docking. The catalytic sites of the
proteases have very different shape from the ATP-binding sites of the protein kinases.
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Moreover, the former show a broad range of surface-hydrophilicity ranging from mainly
hydrophobic (β-secretase) to a strong electrostatic potential (NS3 protease). It is thus
encouraging that docking finds inhibitors for all of them. The six enzymes are involved
in key biological processes in humans or human parasites. Therefore, they are relevant
drug targets: β-secretase in Alzheimer’s disease, cathepsin B in cancer and rheumatic
disorders, EphB4 tyrosine kinase in cancer-related angiogenesis, CDK2 Ser/Thr kinase in
several types of cancer, plasmepsin II in malaria, and NS3 protease in infections caused
by flaviviruses, in particular West Nile virus and Dengue virus. Recently, a series of 50
derivatives of the inhibitor 7 of the EphB4 tyrosine kinase have been synthesized. These
50 compounds were designed using the binding mode obtained by automatic docking.
Notably, six of these compounds are active in the submicromolar range and one of them
has an IC50 value of about 5 nM [116]. It is likely that medicinal chemistry optimization of
all of the inhibitors presented in this review article (i.e., discovered by high-throughput
docking) might yield (low) nanomolar inhibitors but it is very difficult to predict in
advance the eventual improvement in potency.
One essential component of our scoring approach is the use of a force field energy
supplemented by the evaluation of electrostatic solvation effects. The latter are calcu-
lated by models of aqueous solvent based on the continuum dielectric approximation.
For fragment docking, the generalized Born approximation is used for evaluating the
electrostatic component of the binding free energy which includes screened electrostatic
interaction, and protein and fragment desolvation terms [40, 41]. The finite-difference
Poisson equation is employed to calculate electrostatic solvation effects for the poses of
the compounds obtained by flexible ligand docking. The poses are then usually ranked
by the LIECE approach [45, 65].
The two main outcomes of our in silico screening campaigns on six different enzymes
are that the hit rate is rather high (between 3% and 40%) and the most potent inhibitors
have low micromolar affinity and favorable ligand efficiency (Table 1). It is difficult to
compare hit rates reported in different studies due to differences in the libraries employed
for screening and in the affinity thresholds adopted for the definition of hits. Yet, our hit
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rates compare favorably with those reported for experimental high-throughput screening
(0.01% - 0.1%) and fragment-based screening (0.1% - 1%) techniques. Moreover, in
silico screening involves much smaller time, consumables, and labor costs than in vitro
screening.
It was not possible to identify submicromolar inhibitors in the eight high-throughput
docking campaigns (for six different enzymes), probably because one or more of the three
following reasons. First, the libraries of available compounds cover a very small fraction
of the potential druglike molecules. In fact, it has been estimated that the number
of potential fragments with up to 11 heavy atoms (under constraints due to chemical
stability and synthetic feasibility) is on the order of 107 [121], while the number of druglike
molecules with less than 30 heavy atoms is larger than 1060 [122]. Furthermore, it is likely
that the coverage of chemical space is very heterogeneous in the libraries of compounds
that are available. A recent analysis of commercially available compounds suggests that
that the chemical space is skewed mainly towards ligands of G-protein coupled receptors
(10.6% of the compounds in a database of about 1 million small molecules resemble
known ligands of these receptors) with fewer kinase-like ligands (4.2%) and an even
smaller amount of compounds resembling protease inhibitors (2.3%) [123]. Note also
that an 80-nM ATP-competitive inhibitor of casein kinase II has been identified by high-
throughput docking of a subset of the Novartis collection of compounds (about 400000
molecules, which are not in the public domain) [124].
Second, there are significant sources of errors in both the force field and continuum
dielectric model used to approximate solvation effects. As an example polarization effects
are neglected in force fields based on fixed partial charges. A recent extension of the
LIECE model has emphasized the importance of quantum mechanics to capture these
effects, in particular for sets of inhibitors with significant differences in the number of
formal charges [125].
Third, all docking studies presented in this review were performed with a rigid protein.
The rigid-protein approximation, which is required for efficiency reasons, dramatically
restricts the number of favorable poses and results in false negatives. As an example,
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two small-molecule inhibitors of the NS3 protease have been identified by docking into
a molecular dynamics snapshot, which would not have been possible by using the X-ray
structure [98].
In conclusion, we have reviewed our computational tools for fragment-based library
docking and presented applications to six different enzymes. The scoring of poses based
on force field energy with implicit solvation has shown robustness in identifying low
micromolar inhibitors. Therefore, for target proteins of known three-dimensional struc-
ture, the efficiency and high hit rate of our fragment-based docking approach makes it a
cost-effective alternative to experimental screening techniques, in particular in the lead
identification phase of the drug discovery process.
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Protein Enzyme class
Most potent inhibitor
Scoring method Ref.
Cpd.
Proteases
Asp PR 1 0.19 561 17% (12/72) 512000 LIECE 83
Asp PR 2 0.19 538 10% (9/88) 316000 LIECE 84
Asp PR 3 0.25 500 32% (6/19) 40000 Consensus scoring 63
NS3 protease 4 0.33 282 5% (1/22) 12000 LIECE 64
NS3 protease 5 0.34/0.25 298 40% (2/5) 19000 Pose filtering 98
6 0.29/0.28 369 3% (1/29) 48000 Consensus scoring 113
EphB4 7 0.32 337 19% (8/43) 728000 LIECE 115
CDK2 8 0.32 321 3% (1/30) 40000 LIECE 65
Hit ratea
Size of 
libraryAffinity 
(µM)
   Ligand efficiency    
(kcal/mol per non-
hydrogen atom)
MW   
(g/mol)
-secretase 3.0b
-secretase 7.1c
Plasmepsin 2c
Ser PR 40d
Ser PR 2.8c/90d
Cathepsin B Cys PR 4.8/6.7c
Kinases
Tyr kin. 1.5c
Ser/Thr kin. 7.8c
Table 1: The library screening campaigns by fragment-based docking performed at the
University of Zurich. aThe ratio in parentheses is the number of compounds with a
value of the measured affinity below 100 µM divided by the number of molecules tested
experimentally. bCell-based assay. cEnzymatic assay with purified protein in solution.
dBinding affinity measured by nuclear magnetic resonance spectroscopy.
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Figure 1: Schematic picture of the pipeline for automatic docking developed in our group.
The automatic decomposition of the molecules into rigid fragments is carried out by the
program DAIM [43]. The fragments are docked by the program SEED which evaluates the
binding free energy including electrostatic solvation effects [40]. The program FFLD [44]
is used for flexible ligand docking using positions and orientations of fragment triplets
(dashed triangles).
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Figure 2: Low micromolar inhibitors discovered by high-throughput fragment-based dock-
ing into β-secretase (compounds 1 and 2), plasmepsin II (3), West Nile virus NS3 protease
(4 and 5), cathepsin B (6), EphB4 tyrosine kinase (7), and CDK2 Ser/Thr kinase (8).
See Figure 1 for the programs used for docking, and Table 1 for hit rates, sizes of libraries
screened, and experimentally measured affinities.
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Figure 3: Schematic picture of the two in silico screening campaigns against West Nile
virus NS3 protease. Docking of the compounds was performed by DAIM/SEED/FFLD
using the 2fp7 structure of the WNV protease as explained in the text and References
[64, 98].
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Figure 4: The guanidinium groups of inhibitors 4 (top left) and 5 (top right) are involved
in electrostatic interactions with hydrogen bond acceptors in the S1 and S2 pockets of
the West Nile virus NS3 protease, as observed in the X-ray structure of the aldehyde
peptidic inhibitor benzoyl-Nle-Lys-Arg-Arg-H (PDB code 2fp7) (bottom left). Only the
C-terminal dipeptide Arg-Arg-H of the aldehyde inhibitor is shown for clarity. (Bottom
right) Overlap of the poses of compounds 4 and 5, which were generated by fragment-
based docking, with the binding mode of the peptidic inhibitor. The inhibitors are
shown by sticks colored by atom-type with carbon atoms in green, cyan, and yellow for
compound 4, 5, and the peptidic inhibitor, respectively. The surface of WNV NS2B-
NS3pro is colored by electrostatic potential with red and blue for negative and positive
potential, respectively. The figure was prepared using PyMOL (Delano Scientific, San
Carlos, CA) and the APBS program [126] was used for calculation of the electrostatic
surface.
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Figure 5: Graphical representation of the workflow of the ALTA procedure [115]. The
first step is the automatic decomposition [43] of a library of compounds (orange rectangle)
to obtain the pool of fragments. Afterwards, fragments selected based on the binding
site features are docked [40] and ranked according to their binding energy [41]. Poses for
molecules that contain at least one of the top-ranking fragments are then generated by
flexible-ligand docking [44].
